pamidronate has been researched along with Inflammation in 9 studies
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate a possible role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw (ONJ) and to discuss an etiological model." | 7.76 | Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. ( Eufinger, H; Hoefert, S; Schmitz, I; Tannapfel, A, 2010) |
| "A total of 18 cases of osteonecrosis were recorded in the group administered pamidronate and dexamethasone." | 7.76 | An experimental study of bisphosphonate-induced jaws osteonecrosis in Sprague-Dawley rats. ( Camacho-Alonso, F; Gómez-García, F; López-Jornet, P; Molina-Miñano, F; Vicente-Ortega, V, 2010) |
| " Common step 2-3 treatments were pamidronate, methotrexate, and TNF-a-inhibition (anti-TNFα), the latter two regarded especially convenient to co-target extra-skeletal inflammation in SAPHO syndrome." | 4.31 | Diagnostic and therapeutic practices in adult chronic nonbacterial osteomyelitis (CNO). ( Appelman-Dijkstra, NM; Clunie, G; Dekkers, OM; Koutrouba, E; Leerling, AT; Winter, EM, 2023) |
| "The aim of this study was to evaluate a possible role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw (ONJ) and to discuss an etiological model." | 3.76 | Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. ( Eufinger, H; Hoefert, S; Schmitz, I; Tannapfel, A, 2010) |
| "A total of 18 cases of osteonecrosis were recorded in the group administered pamidronate and dexamethasone." | 3.76 | An experimental study of bisphosphonate-induced jaws osteonecrosis in Sprague-Dawley rats. ( Camacho-Alonso, F; Gómez-García, F; López-Jornet, P; Molina-Miñano, F; Vicente-Ortega, V, 2010) |
| " As clinical indications of intravenous bisphosphonates continue to expand, prescribing clinicians should be familiar with these possible adverse effects and discuss them with patients before commencing or continuing on therapy." | 2.43 | Management of the adverse effects associated with intravenous bisphosphonates. ( Stiff, PJ; Tanvetyanon, T, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Abdou, WM | 1 |
| Ganoub, NA | 1 |
| Geronikaki, A | 1 |
| Sabry, E | 1 |
| Leerling, AT | 1 |
| Clunie, G | 1 |
| Koutrouba, E | 1 |
| Dekkers, OM | 1 |
| Appelman-Dijkstra, NM | 1 |
| Winter, EM | 1 |
| Hoefert, S | 1 |
| Schmitz, I | 1 |
| Tannapfel, A | 1 |
| Eufinger, H | 1 |
| Senel, FC | 1 |
| Kadioglu Duman, M | 1 |
| Muci, E | 1 |
| Cankaya, M | 1 |
| Pampu, AA | 1 |
| Ersoz, S | 1 |
| Gunhan, O | 1 |
| López-Jornet, P | 1 |
| Camacho-Alonso, F | 1 |
| Molina-Miñano, F | 1 |
| Gómez-García, F | 1 |
| Vicente-Ortega, V | 1 |
| Christidou, F | 1 |
| Bamichas, G | 1 |
| Stangou, M | 1 |
| Natse, T | 1 |
| Kalpakidis, V | 1 |
| Sombolos, K | 1 |
| Conti, L | 1 |
| Casetti, R | 1 |
| Cardone, M | 1 |
| Varano, B | 1 |
| Martino, A | 1 |
| Belardelli, F | 1 |
| Poccia, F | 1 |
| Gessani, S | 1 |
| Tanvetyanon, T | 1 |
| Stiff, PJ | 1 |
| Mandey, SH | 1 |
| Kuijk, LM | 1 |
| Frenkel, J | 1 |
| Waterham, HR | 1 |
1 review available for pamidronate and Inflammation
| Article | Year |
|---|---|
Management of the adverse effects associated with intravenous bisphosphonates.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Inflamm | 2006 |
8 other studies available for pamidronate and Inflammation
| Article | Year |
|---|---|
Synthesis, properties, and perspectives of gem-diphosphono substituted-thiazoles.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; Bone Resorption; | 2008 |
Diagnostic and therapeutic practices in adult chronic nonbacterial osteomyelitis (CNO).
Topics: Acquired Hyperostosis Syndrome; Adult; Child; Humans; Hyperostosis; Inflammation; Osteitis; Osteomye | 2023 |
Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Connective Tissue; Di | 2010 |
Jaw bone changes in rats after treatment with zoledronate and pamidronate.
Topics: Animals; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Female; Femur; Im | 2010 |
An experimental study of bisphosphonate-induced jaws osteonecrosis in Sprague-Dawley rats.
Topics: Animals; Bone Density Conservation Agents; Dexamethasone; Diphosphonates; Drug Combinations; Glucoco | 2010 |
Tumoral calcinosis inducing systemic inflammatory response in a hemodialysis patient.
Topics: Aged; Calcinosis; Diphosphonates; Hip Joint; Hip Prosthesis; Humans; Inflammation; Male; Pamidronate | 2002 |
Reciprocal activating interaction between dendritic cells and pamidronate-stimulated gammadelta T cells: role of CD86 and inflammatory cytokines.
Topics: Anti-Inflammatory Agents; Antigens, CD; B7-2 Antigen; Cell Communication; Cytokines; Dendritic Cells | 2005 |
A role for geranylgeranylation in interleukin-1beta secretion.
Topics: Anti-Inflammatory Agents; Bodily Secretions; Diphosphonates; Humans; Hydroxymethylglutaryl-CoA Reduc | 2006 |